[Effect of trimebutine on the motility of the normal human small intestines: mechanism of action].
The effects of intravenous trimebutine (TMB) on duodenojejunal motility were investigated in normal subjects in fed and fasted states. The motility was recorded manometrically. In the fasting state TMB 100 mg, 25 min after a spontaneous phase 3 (P3) constantly induced a premature P3. The mean period (means +/- SE) of the migrating motor complex (MMC) cycle decreased from 84 +/- 10.9 to 32.5 +/- 1.0 min. TMB 50 mg, 3 and 25 min after a spontaneous P3 did not significantly modify the periodicity of MMC. TMB 100 mg initiated P3-like activity in post-prandial state. Previous administration of a low dose of naloxone suppressed the stimulating action of TMB. After a TMB injection the motilin plasma level did not vary; a brief increated of PP plasma level was observed. It may be concluded that in the human small intestine TMB included a typical modification of the motility pattern. Opiate receptors might be involved.
D000328:Adult; D001565:Benzoates / Q000494:pharmacology*; D004386:Duodenum / Q000187:drug effects; D005502:Food; D005508:Food Deprivation; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D007275:Injections, Intravenous; D007421:Intestine, Small / Q000187:drug effects* / Q000502:physiology; D009037:Motilin / Q000097:blood; D009270:Naloxone / Q000494:pharmacology; D014287:Trimebutine / Q000008:administration & dosage / Q000494:pharmacology*
D001565:Benzoates; D009270:Naloxone; D009037:Motilin; D014287:Trimebutine
Effet de la trimébutine sur la motricité de l'intestin grêle proximal chez l'homme normal: mécanisme d'action.